Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lapatinib + topotecan
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of lapatinib, a dual tyrosine kinase inhibitor targeting EGFR and HER2, and topotecan, a topoisomerase I inhibitor. Lapatinib also inhibits breast cancer resistance protein (BCRP) and P-glycoprotein (Pgp), which are transporters involved in topotecan resistance. The combination was developed to potentially overcome resistance to topotecan through lapatinib's inhibition of these drug efflux transporters.
- Other names
- lapatinib + topotecan
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on lapatinib + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lapatinib + topotecan.